title: Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine.
abstract: DNA-based vaccine immunization effectively induces both humoral and cell-mediated immunity to antigens and can confer protection against numerous infectious diseases as well as some cancers. Human and mouse melanomas consistently express the tumor-associated antigen interacted with the melanogenesis pathway. Gp100 is immunogenic and has been shown to induce both antibody and cytotoxic T cell (CTL) responses in humans. To explore the potential use of DNA immunization to induce melanoma-specific immune responses, we assessed HVJ-AVE liposome incorporated with plasmid DNA encoding human gp100. The gp100 DNA vaccine was used in a mouse melanoma model to assess immunity against the B16 melanoma of C57BL/6 mice. Intramuscular injection of the DNA-HVJ-AVE liposomes induced both anti-gp100 antibody and CTL responses. Gp100 DNA-HVJ-AVE liposome immunization significantly delayed tumor development in mice challenged with B16 melanoma cells. Mice immunized with gp100 DNA-HVJ-AVE liposomes survived longer compared with control mice immunized with HVJ-AVE liposome alone. These results indicate that immunization with human gp100 DNA by HVJ-AVE liposomes can induce protective immunity against melanoma in this pre-clinical mouse model. This strategy may provide an effective approach for vaccine therapy with tumor-associated antigens against human melanoma.
authors.affiliation: Division of Gene Therapy Science, Osaka University School of Medicine, Suita, Osaka, Japan.
authors.forename: W Z
authors.initials: WZ
authors.lastname: Zhou
authors.forename: Y
authors.initials: Y
authors.lastname: Kaneda
authors.forename: S
authors.initials: S
authors.lastname: Huang
authors.forename: R
authors.initials: R
authors.lastname: Morishita
authors.forename: D
authors.initials: D
authors.lastname: Hoon
mesh_terms: D000818:Animals; D000912:Antibodies, Neoplasm / Q000097:blood; D019496:Cancer Vaccines / Q000008:administration & dosage*; D015316:Genetic Therapy / Q000379:methods*; D007114:Immunization; D007273:Injections, Intramuscular; D008081:Liposomes; D008297:Male; D008546:Melanoma, Experimental / Q000276:immunology / Q000628:therapy*; D008562:Membrane Glycoproteins / Q000235:genetics*; D051379:Mice; D008810:Mice, Inbred C57BL; D009363:Neoplasm Proteins / Q000235:genetics*; D009368:Neoplasm Transplantation; D018108:Respirovirus / Q000235:genetics; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage*; D058951:gp100 Melanoma Antigen
chemical_list: D000912:Antibodies, Neoplasm; D019496:Cancer Vaccines; D008081:Liposomes; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; C548637:PMEL protein, human; C548642:Pmel protein, mouse; D019444:Vaccines, DNA; D058951:gp100 Melanoma Antigen